🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
December 15, 2025 at 8:22 PM
🚨 UPDATE: The @fda.gov has approved a new therapy for #marginalzonelymphoma. The approval is based on results from a phase 2 clinical trial led by Dr. Lia Palomba, a hematologist-oncologist at MSK.
Learn more: bit.ly/4iVd9Y6
Learn more: bit.ly/4iVd9Y6
#NICE #EliLilly #Omvoh #Crohnsdisease #BeOneMedicine #Brukinsa #mantlecelllymphoma #ulcerativecolitis #NICEguidance #gastroenterology #SMC #Brukinsa #relapsedMCL #refractoryMCL #Waldenstromsmacroglobulinaemia #chroniclymphocyticleukaemia #marginalzonelymphoma
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
NICE backs new drugs for Crohn's disease, lymphoma
Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
pharmaphorum.com
July 15, 2025 at 8:45 AM
#BristolMyersSquibb has taken #CARTtherapy of #bloodcancers into new territory, after getting #FDAapproval for Breyanzi as a treatment for relapsed or refractory #marginalzonelymphoma (MZL).
pharmaphorum.com/news/bmss-br...
pharmaphorum.com/news/bmss-br...
BMS's Breyanzi is first CAR-T for marginal zone lymphoma
Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
pharmaphorum.com
December 5, 2025 at 11:53 AM
#BristolMyersSquibb has taken #CARTtherapy of #bloodcancers into new territory, after getting #FDAapproval for Breyanzi as a treatment for relapsed or refractory #marginalzonelymphoma (MZL).
pharmaphorum.com/news/bmss-br...
pharmaphorum.com/news/bmss-br...
The @fda.gov has approved Breyanzi® for the treatment of adult patients with R/R #marginalZoneLymphoma who have received at least 2 prior lines of systemic therapy. From @medicalprofref.bsky.social.
https://bit.ly/3KRugOc
#MZL #lymsm
https://bit.ly/3KRugOc
#MZL #lymsm
FDA Greenlights First CAR T-Cell Therapy for Marginal Zone Lymphoma
The FDA has approved Breyanzi for the treatment of adult patients with R/R MZL who have received at least 2 prior lines of systemic therapy.
bit.ly
December 18, 2025 at 3:55 PM
The @fda.gov has approved Breyanzi® for the treatment of adult patients with R/R #marginalZoneLymphoma who have received at least 2 prior lines of systemic therapy. From @medicalprofref.bsky.social.
https://bit.ly/3KRugOc
#MZL #lymsm
https://bit.ly/3KRugOc
#MZL #lymsm
#Lymphopoiesiscont36
#NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations
#NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations
November 14, 2025 at 1:30 PM